The
von Hippel–Lindau tumor suppressor gene (VHL) has attracted intensive interest
not only because its mutations predispose carriers to devastating tumors, but
also because it is involved in oxygen sensing under physiological conditions.
VHL loss-of-function mutations result in organ-specific tumors, such as
hemangioblastoma of the central nervous system and renal cell carcinoma, both
untreatable with conventional chemotherapies. The VHL protein is best known as
an E3 ubiquitin ligase that targets hypoxia-inducible factor-α
(HIF-α), but many diverse, non-canonical cellular functions have also been
assigned to VHL, mainly based on studies in cell culture systems. As such,
although the HIF-dependent role of VHL is critical, the full spectrum of
pathophysiological functions of VHL is still unresolved. Such understanding
requires careful cross-referencing with physiologically relevant experimental
models. Studies in model systems, such as Caenorhabditis elegans, Drosophila,
zebrafish and mouse have provided critical in vivo confirmation of the VHL–HIF
pathway, and verification of potentially important cellular functions including
microtubule stabilization and epithelial morphogenesis. More recently, animal
models have also suggested systemic roles of VHL in hematopoiesis, metabolic
homeostasis and inflammation. In this review, the studies performed in model
organisms will be summarized and placed in context with existing clinical and
in vitro data.
Source: Complex
cellular functions of the von Hippel–Lindau tumor suppressor gene: insights
from model organisms. T Hsu (tienh@bu.edu).
Oncogene (2012) 31, 2247–2257.
Free
paper available at:
Aucun commentaire:
Enregistrer un commentaire